← Leaderboards
Mark E Gurney
Tetra Discovery Partners, Inc.
$13,379,130
Attributed
$13,379,130
Total exposure
7
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $3M · FY2011–20$5M$3.8M$2.5M$1.3M$0
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
Funding mix
By agency
NIH$13,379,130 · 7
By mechanism
R44$10,119,228 · 3
U01$1,992,974 · 1
R43$1,041,929 · 2
R41$224,999 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Cognition”
- David R. Weir · University Of Michigan At Ann Arbor$380,402,429
- Paul S. Aisen · Cognition Therapeutics, Inc.$185,453,129
- Randall J Bateman · Washington University$179,917,643
- Reisa A. Sperling · Banner Health$160,454,465
- Michael W Weiner · Northern California Institute Res &Educ$153,571,751
- Ronald C Petersen · Mayo Clinic Coll Of Medicine, Rochester$118,618,221
Research focus
CognitionBaseBrainInhibitor/AntagonistClinical TrialsPharmaceutical PreparationsDoseLeadMental DepressionToxic EffectDesignStructureIn VivoPlasmaFundingIn VitroPhosphodiesterase 4dCognitiveGenotoxicitySmall Business Innovation Research GrantPathologyAlzheimer&AposMemoryImpaired Cognition
Grant awards (24)
PDE4D PET Ligand$625,084
R44 · FY2020 · MH · contact PI
Phosphodiesterase-4B (PDE4B) Inhibitors for Psychiatric Disease$982,403
R44 · FY2018 · MH · contact PI
PDE4D PET Ligand$952,592
R44 · FY2018 · MH · contact PI
Phosphodiesterase-4B (PDE4B) Inhibitors for Alzheimer's Disease$412,485
R44 · FY2018 · MH · contact PI
Phosphodiesterase-4B (PDE4B) Inhibitors for Psychiatric Disease$986,995
R44 · FY2017 · MH · contact PI
BPN14770 Safety and Cognitive Effect in Young and Elderly Subjects$108,668
R44 · FY2017 · AG · contact PI
BPN14770 Safety and Cognitive Effect in Young and Elderly Subjects$2,055,899
R44 · FY2016 · AG · contact PI
Phosphodiesterase-4B (PDE4B) Inhibitors for Psychiatric Disease$991,394
R44 · FY2016 · MH · contact PI
PDE4D Allosteric Modulators for Treating Cognitive Impairment$1
U01 · FY2016 · NS · contact PI
PDE4B Inhibitors For Treating Major Depression$1,006,069
R44 · FY2015 · MH · contact PI
BPN14770 Phase 1 Single Ascending Dose Clinical Trial in Healthy Subjects$694,703
U01 · FY2015 · NS · contact PI
PDE4D PET Ligand for Psychiatric Disease$346,237
R43 · FY2015 · MH · contact PI
PDE4D Allosteric Modulators for Treating Cognitive Impairment$300,834
U01 · FY2015 · NS · contact PI
PDE4B Inhibitors for Treating Brain Injury$224,999
R41 · FY2015 · NS · contact PI
PDE4B Inhibitors For Treating Major Depression$989,992
R44 · FY2014 · MH · contact PI
PDE4D Allosteric Modulators for Treating Cognitive Impairment$235,406
U01 · FY2014 · NS · contact PI
PDE4D-NAMs for Treating Cognitive Impairment$96,942
U01 · FY2014 · NS · contact PI
PDE4B Inhibitors For Treating Major Depression$1,007,647
R44 · FY2013 · MH · contact PI
PDE4D Allosteric Modulators for Treating Cognitive Impairment$235,406
U01 · FY2013 · NS · contact PI
PDE4D Allosteric Modulators for Treating Cognitive Impairment$140,626
U01 · FY2013 · NS · contact PI
PDE4D Allosteric Modulators for Treating Cognitive Impairment$53,650
U01 · FY2013 · NS · contact PI
Phosphodiesterase 4 Subtype Selective Modulators for Psychiatric Disease$345,692
R43 · FY2012 · MH · contact PI
PDE4D Allosteric Modulators for Treating Cognitive Impairment$235,406
U01 · FY2012 · NS · contact PI
Phosphodiesterase Type IV (PDE4) Isoform Selective Allosteric Modulators For Psyc$350,000
R43 · FY2011 · MH · contact PI